A Study of Sovilnesib in Subjects With Ovarian Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

April 4, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

April 30, 2026

Conditions
High Grade Serous Adenocarcinoma of OvaryFallopian Tube CancerPrimary Peritoneal CarcinomaChromosomal Instability
Interventions
DRUG

Sovilnesib

Sovilnesib tablets will be given orally.

Trial Locations (13)

10128

Icahn School of Medicine at Mount Sinai, New York

14263

Roswell Park Comprehensive Cancer Center, Buffalo

21287

Johns Hopkins Hospital, Baltimore

29020

MUSC Hollings Cancer Center, Charleston

30912

Georgia Cancer Center Augusta University, Atlanta

35294

The University of Alabama at Birmingham, Birmingham

49503

Corewell Health, Grand Rapids

72205

University of Arkansas for Medical Sciences, Little Rock

73117

OU Health Stephenson Cancer Center, Oklahoma City

90095

UCLA, Los Angeles

92663

Hoag Memorial Hospital, Newport Beach

98109

Fred Hutchinson Cancer Center, Seattle

02215

Dana Farber Cancer Institute, Boston

All Listed Sponsors
lead

Volastra Therapeutics, Inc.

INDUSTRY

NCT06084416 - A Study of Sovilnesib in Subjects With Ovarian Cancer | Biotech Hunter | Biotech Hunter